Shionogi & Co Ltd Involvement in ViiV Healthcare Announcement

Shionogi & Co Ltd has been involved in the announcement of APRETUDE’s coverage under Canada’s Non-Insured Health Benefits (NIHB) Program for HIV-1 pre-exposure prophylaxis (PrEP).

As a shareholder of ViiV Healthcare, Shionogi & Co Ltd has contributed to the expansion of HIV prevention options in Canada. The NIHB Program provides coverage for APRETUDE, a treatment for HIV-1 PrEP, making it more accessible to at-risk individuals.

Key Details

• APRETUDE is now covered under Canada’s Non-Insured Health Benefits (NIHB) Program for HIV-1 pre-exposure prophylaxis (PrEP)
• The treatment is intended to make HIV prevention more accessible to at-risk individuals, particularly in Indigenous communities
• Shionogi & Co Ltd’s involvement in ViiV Healthcare has contributed to the expansion of HIV prevention options in Canada

Program Details

• The Non-Insured Health Benefits (NIHB) Program provides coverage for APRETUDE, a treatment for HIV-1 PrEP
• The program aims to make HIV prevention more accessible to at-risk individuals, including those in Indigenous communities